The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 27, 2016
Filed:
Apr. 09, 2015
Applicants:
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Institut Pasteur DE Lille, Lille, FR;
Universite Droit ET Sante Lille Ii, Lille, FR;
Inventors:
Assignees:
UNIVERSITÉ DROIT ET SANTÉ LILLE II, Lille, FR;
INSERM, Paris, FR;
INSTITUT PASTEUR DE LILLE, Lille, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 1/36 (2006.01); A61K 39/02 (2006.01); C07K 14/235 (2006.01); A61K 39/09 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 1/36 (2013.01); A61K 39/092 (2013.01); A61K 39/099 (2013.01); A61K 39/12 (2013.01); C07K 14/235 (2013.01); A61K 2039/522 (2013.01); A61K 2039/523 (2013.01); A61K 2039/543 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/18534 (2013.01);
Abstract
A genetically attenuatedstrain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.